具有双通道通气和恒定泄气量功能的新型无创正压通气面罩治疗慢性阻塞性肺疾病急性加重合并CO_(2)潴留患者的临床效果研究  

Clinical Application of a Novel Noninvasive Positive Pressure Ventilation Face Mask with Two Channels and Constant Leakage for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Carbon Dioxide Retention

作　　者：黄桃[1,2] 罗娜 罗松[1] 徐钦 HUANG Tao;LUO Na;LUO Song;XU Qin(ICU,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Medical Data Science Academy,Chongqing Medical University,Chongqing 400016,China;Department of General Medicine,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第一医院重症医学科,重庆市400016 [2]重庆医科大学医学数据研究院,重庆市400016 [3]重庆医科大学附属第二医院全科医学科,重庆市400010

出　　处：《中国全科医学》2023年第3期343-347,355,共6页Chinese General Practice

基　　金：重庆市科卫联合医学科研项目(2022MSXM032);2021年重庆医科大学智慧医学研究项目(ZHYX202107);重庆医科大学附属第一医院管理科研基金项目(GLJJ2021-01)。

摘　　要：背景无创正压通气(NPPV)是治疗慢性阻塞性肺疾病急性加重(AECOPD)合并CO_(2)潴留患者的重要呼吸支持技术。但现有NPPV面罩内存在明显无效腔效应,容易导致CO_(2)重复呼吸而影响患者CO_(2)潴留的纠正。目的研发一种具有双通道通气和恒定泄气量功能的NPPV面罩(即TCCL面罩),并探讨其在NPPV治疗AECOPD合并CO_(2)潴留患者中的价值。方法选择重庆医科大学附属第一医院重症医学科2020-2021年收治的30例AECOPD合并Ⅱ型呼吸衰竭行NPPV治疗的患者为研究对象。根据不同的NPPV面罩类型随机分为试验组(n=15)和对照组(n=15)。试验组采用TCCL面罩;对照组采用传统NPPV面罩和侧孔型呼气阀的组合。监测两组NPPV治疗0 h、4 h、8 h、24 h、48 h及停止NPPV 24 h的动脉血氧分压(PaO_(2))和二氧化碳分压(PaCO_(2))水平。结果两因素重复测量方差分析结果可见,时间和组间对PaO_(2)、PaCO_(2)不存在交互作用(P>0.05),时间对PaO_(2)、PaCO_(2)主效应显著(P<0.001),组间对PaO_(2)主效应不显著(F_(组间)=0.153,P_(组间)=0.699),组间对PaCO_(2)主效应显著(F_(组间)=5.129,P_(组间)=0.031)。两组治疗0 h的PaO_(2)水平均低于治疗4 h、8 h、24 h、48 h及停止NPPV 24 h(P<0.05);两组治疗4 h的PaO_(2)水平均低于治疗8 h、24 h、48 h及停止NPPV 24 h(P<0.05);两组治疗8 h的PaO_(2)水平均低于治疗48 h及停止NPPV 24 h(P<0.05);对照组治疗24 h的PaO_(2)水平低于治疗48 h(P<0.05);试验组治疗24 h的PaO_(2)水平低于治疗48 h及停止NPPV 24 h(P<0.05);相同时间点两组间PaO_(2)水平比较,差异无统计学意义(P>0.05)。试验组治疗4 h、8 h、24 h的PaCO_(2)水平低于对照组(P<0.05)。两组治疗0 h时PaCO_(2)水平高于治疗4 h、8 h、24 h、48 h及停止NPPV 24 h(P<0.05),两组治疗4 h时PaCO_(2)水平高于治疗8 h、24 h、48 h及停止NPPV 24 h(P<0.05),两组治疗8 h的PaCO_(2)水平高于治疗24 h、48 h及停止NPPV 24 h(P<0.05)。对照组治疗24 h时PaCO_(2)水Background Noninvasive positive pressure ventilation(NPPV)is a major respiratory support technique for patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and carbon dioxide(CO_(2)) retention.However,the obvious dead space in available masks used for NPPV could easily lead to repeated CO_(2) inhalation,which affects the correction of CO_(2) retention.Objective To develop a face mask with two channel and constant leakage(TCCL)used for NPPV,and to examine its value in NPPV treatment of AECOPD patients with CO_(2) retention.Methods Thirty patients with AECOPD and typeⅡrespiratory failure treated with NPPV were recruited from the ICU,the First Affiliated Hospital of Chongqing Medical University from 2020 to 2021,and equally randomized into an experimental group(using the TCCL mask)and an control group(using the traditional mask with an exhalation valve on the side for NPPV).Treatment effectiveness was assessed using arterial partial pressure of oxygen(PaO_(2)) and partial pressure of carbon dioxide(PaCO_(2)) monitored at baseline,and at the end of 4,8,24,and 48 hours of NPPV treatment as well as 24 hours after NPPV cessation.Results The two-way repeated measures ANOVA indicated that treatment time and treatment approach had no interactive effects on PaO_(2)(P>0.05).Treatment time produced significant main effects on PaO_(2)(P<0.001),while treatment approach did not(F=0.153,P=0.699).In both groups,the level of PaO_(2) at baseline was lower than that at the end of 4,8,24,and 48 hours of NPPV treatment and 24 hours after NPPV cessation(P<0.05);the level of PaO_(2) at the end of 4 hours of treatment was lower than that measured at the subsequent four time points(P<0.05);the PaO_(2) level at the end of 8 hours of treatment was lower than that at 48 hours of treatment and 24 hours after NPPV cessation(P<0.05).The PaO_(2) level at 24 hours of treatment was lower than that at 48 hours of treatment in the control group(P<0.05).The PaO_(2) level at 24 hours of treatment was lower than that at 48

关 键 词：肺疾病 慢性阻塞性 肺疾病 呼吸衰竭 面罩 血气分析 正压呼吸 专利 治疗结果 无创正压通气 

分 类 号：R563.9[医药卫生—呼吸系统]